Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 583
Filtrar
Más filtros

Intervalo de año de publicación
1.
Rev Endocr Metab Disord ; 25(4): 707-725, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38556561

RESUMEN

Hepatic glycogen storage diseases constitute a group of disorders due to defects in the enzymes and transporters involved in glycogen breakdown and synthesis in the liver. Although hypoglycemia and hepatomegaly are the primary manifestations of (most of) hepatic GSDs, involvement of the endocrine system has been reported at multiple levels in individuals with hepatic GSDs. While some endocrine abnormalities (e.g., hypothalamic­pituitary axis dysfunction in GSD I) can be direct consequence of the genetic defect itself, others (e.g., osteopenia in GSD Ib, insulin-resistance in GSD I and GSD III) may be triggered by the (dietary/medical) treatment. Being aware of the endocrine abnormalities occurring in hepatic GSDs is essential (1) to provide optimized medical care to this group of individuals and (2) to drive research aiming at understanding the disease pathophysiology. In this review, a thorough description of the endocrine manifestations in individuals with hepatic GSDs is presented, including pathophysiological and clinical implications.


Asunto(s)
Enfermedad del Almacenamiento de Glucógeno , Humanos , Enfermedad del Almacenamiento de Glucógeno/metabolismo , Enfermedad del Almacenamiento de Glucógeno/fisiopatología , Hepatopatías/metabolismo , Hepatopatías/fisiopatología , Hepatopatías/etiología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/fisiopatología , Hígado/metabolismo , Hígado/fisiopatología
2.
Proc Natl Acad Sci U S A ; 118(19)2021 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-33941690

RESUMEN

Alopecia, neurologic defects, and endocrinopathy (ANE) syndrome is a rare ribosomopathy known to be caused by a p.(Leu351Pro) variant in the essential, conserved, nucleolar large ribosomal subunit (60S) assembly factor RBM28. We report the second family of ANE syndrome to date and a female pediatric ANE syndrome patient. The patient presented with alopecia, craniofacial malformations, hypoplastic pituitary, and hair and skin abnormalities. Unlike the previously reported patients with the p.(Leu351Pro) RBM28 variant, this ANE syndrome patient possesses biallelic precursor messenger RNA (pre-mRNA) splicing variants at the 5' splice sites of exon 5 (ΔE5) and exon 8 (ΔE8) of RBM28 (NM_018077.2:c.[541+1_541+2delinsA]; [946G > T]). In silico analyses and minigene splicing experiments in cells indicate that each splice variant specifically causes skipping of its respective mutant exon. Because the ΔE5 variant results in an in-frame 31 amino acid deletion (p.(Asp150_Lys180del)) in RBM28 while the ΔE8 variant leads to a premature stop codon in exon 9, we predicted that the ΔE5 variant would produce partially functional RBM28 but the ΔE8 variant would not produce functional protein. Using a yeast model, we demonstrate that the ΔE5 variant does indeed lead to reduced overall growth and large subunit ribosomal RNA (rRNA) production and pre-rRNA processing. In contrast, the ΔE8 variant is comparably null, implying that the partially functional ΔE5 RBM28 protein enables survival but precludes correct development. This discovery further defines the underlying molecular pathology of ANE syndrome to include genetic variants that cause aberrant splicing in RBM28 pre-mRNA and highlights the centrality of nucleolar processes in human genetic disease.


Asunto(s)
Alopecia/metabolismo , Nucléolo Celular/metabolismo , Enfermedades del Sistema Endocrino/metabolismo , Discapacidad Intelectual/metabolismo , Empalme del ARN , Proteínas de Unión al ARN/metabolismo , Subunidades Ribosómicas Grandes/metabolismo , Adulto , Alopecia/genética , Brasil , Enfermedades del Sistema Endocrino/genética , Exones , Femenino , Células HEK293 , Cabello/metabolismo , Humanos , Lactante , Discapacidad Intelectual/genética , Masculino , Linaje , Precursores del ARN/metabolismo , Procesamiento Postranscripcional del ARN , ARN Ribosómico/genética , ARN Ribosómico/metabolismo , Subunidades Ribosómicas Grandes/genética , Saccharomyces cerevisiae , Adulto Joven
3.
Int J Mol Sci ; 25(18)2024 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-39337343

RESUMEN

Sodium imbalance is a common electrolyte disturbance in COVID-19, often linked to disruptions in hormonal regulation. This review explores the relationship between sodium dysregulation and endocrine disturbances, particularly focusing on primary and secondary hypothyroidism, hypocortisolism, and the renin-angiotensin-aldosterone system (RAAS). Hypocortisolism in COVID-19, due to adrenal insufficiency or secondary to pituitary dysfunction, can lead to hyponatremia through inadequate cortisol levels, which impair renal free water excretion and enhance antidiuretic hormone (ADH) secretion. Similarly, hypothyroidism is associated with decreased renal blood flow and the glomerular filtration rate (GFR), which also increases ADH activity, leading to water retention and dilutional hyponatremia. Furthermore, COVID-19 can disrupt RAAS (primarily through its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor), diminishing aldosterone secretion and further contributing to sodium loss and hyponatremia. These hormonal disruptions suggest that sodium imbalance in COVID-19 is multifactorial and warrants further investigation into the complex interplay between COVID-19, endocrine function, and sodium homeostasis. Future research should focus on understanding these mechanisms to develop management algorithms that address both sodium imbalance and underlying hormonal disturbances in order to improve prognosis and outcomes in COVID-19 patients.


Asunto(s)
COVID-19 , Hiponatremia , Sistema Renina-Angiotensina , SARS-CoV-2 , Humanos , COVID-19/complicaciones , COVID-19/metabolismo , Hiponatremia/etiología , Hiponatremia/metabolismo , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/metabolismo , Sodio/metabolismo , Hipotiroidismo/metabolismo , Hipotiroidismo/complicaciones
4.
Int J Mol Sci ; 25(15)2024 Aug 02.
Artículo en Inglés | MEDLINE | ID: mdl-39126035

RESUMEN

Lipid metabolism is a critical component in preserving homeostasis and health, and lipids are significant chemicals involved in energy metabolism in living things. With the growing interest in lipid metabolism in recent years, an increasing number of studies have demonstrated the close relationship between abnormalities in lipid metabolism and the development of numerous human diseases, including cancer, cardiovascular, neurological, and endocrine system diseases. Thus, understanding how aberrant lipid metabolism contributes to the development of related diseases and how it works offers a theoretical foundation for treating and preventing related human diseases as well as new avenues for the targeted treatment of related diseases. Therefore, we discuss the processes of aberrant lipid metabolism in various human diseases in this review, including diseases of the cardiovascular system, neurodegenerative diseases, endocrine system diseases (such as obesity and type 2 diabetes mellitus), and other diseases including cancer.


Asunto(s)
Metabolismo de los Lípidos , Neoplasias , Enfermedades Neurodegenerativas , Humanos , Neoplasias/metabolismo , Neoplasias/etiología , Neoplasias/patología , Animales , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/patología , Enfermedades Cardiovasculares/metabolismo , Enfermedades Cardiovasculares/etiología , Obesidad/metabolismo , Enfermedades del Sistema Endocrino/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/patología , Trastornos del Metabolismo de los Lípidos/metabolismo
5.
Nucleic Acids Res ; 49(D1): D1218-D1224, 2021 01 08.
Artículo en Inglés | MEDLINE | ID: mdl-32941628

RESUMEN

Infertility is a complex multifactorial disease that affects up to 10% of couples across the world. However, many mechanisms of infertility remain unclear due to the lack of studies based on systematic knowledge, leading to ineffective treatment and/or transmission of genetic defects to offspring. Here, we developed an infertility disease database to provide a comprehensive resource featuring various factors involved in infertility. Features in the current IDDB version were manually curated as follows: (i) a total of 307 infertility-associated genes in human and 1348 genes associated with reproductive disorder in 9 model organisms; (ii) a total of 202 chromosomal abnormalities leading to human infertility, including aneuploidies and structural variants; and (iii) a total of 2078 pathogenic variants from infertility patients' samples across 60 different diseases causing infertility. Additionally, the characteristics of clinically diagnosed infertility patients (i.e. causative variants, laboratory indexes and clinical manifestations) were collected. To the best of our knowledge, the IDDB is the first infertility database serving as a systematic resource for biologists to decipher infertility mechanisms and for clinicians to achieve better diagnosis/treatment of patients from disease phenotype to genetic factors. The IDDB is freely available at http://mdl.shsmu.edu.cn/IDDB/.


Asunto(s)
Aberraciones Cromosómicas , Bases de Datos Factuales , Enfermedades del Sistema Endocrino/genética , Infertilidad Femenina/genética , Infertilidad Masculina/genética , Mutación , Animales , Mapeo Cromosómico , Modelos Animales de Enfermedad , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/patología , Femenino , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Predisposición Genética a la Enfermedad , Genoma Humano , Humanos , Infertilidad Femenina/metabolismo , Infertilidad Femenina/patología , Infertilidad Masculina/metabolismo , Infertilidad Masculina/patología , Internet , Masculino , Oocitos/metabolismo , Oocitos/patología , Programas Informáticos , Espermatozoides/metabolismo , Espermatozoides/patología
6.
Int J Mol Sci ; 22(22)2021 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-34830210

RESUMEN

Misfolding of G protein-coupled receptors (GPCRs) caused by mutations frequently leads to disease due to intracellular trapping of the conformationally abnormal receptor. Several endocrine diseases due to inactivating mutations in GPCRs have been described, including X-linked nephrogenic diabetes insipidus, thyroid disorders, familial hypocalciuric hypercalcemia, obesity, familial glucocorticoid deficiency [melanocortin-2 receptor, MC2R (also known as adrenocorticotropin receptor, ACTHR), and reproductive disorders. In these mutant receptors, misfolding leads to endoplasmic reticulum retention, increased intracellular degradation, and deficient trafficking of the abnormal receptor to the cell surface plasma membrane, causing inability of the receptor to interact with agonists and trigger intracellular signaling. In this review, we discuss the mechanisms whereby mutations in GPCRs involved in endocrine function in humans lead to misfolding, decreased plasma membrane expression of the receptor protein, and loss-of-function diseases, and also describe several experimental approaches employed to rescue trafficking and function of the misfolded receptors. Special attention is given to misfolded GPCRs that regulate reproductive function, given the key role played by these particular membrane receptors in sexual development and fertility, and recent reports on promising therapeutic interventions targeting trafficking of these defective proteins to rescue completely or partially their normal function.


Asunto(s)
Enfermedades del Sistema Endocrino/genética , Enfermedades del Sistema Endocrino/metabolismo , Mutación , Receptores Acoplados a Proteínas G/química , Receptores Acoplados a Proteínas G/genética , Animales , Membrana Celular/metabolismo , Retículo Endoplásmico/metabolismo , Humanos , Pliegue de Proteína , Transporte de Proteínas , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Gonadotropina/metabolismo , Transducción de Señal/genética
7.
Immunology ; 159(2): 167-177, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31646612

RESUMEN

Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in cancer medicine, having contributed to a widening of therapeutic options across oncological indications. Disruption of immune tolerance is the key mechanism of action of checkpoint inhibitors and although immune-related adverse events are a typical class effect of these compounds, the relationship between toxicity and response is not fully understood. Awareness and vigilance are paramount in recognizing potentially life-threatening toxicities and managing them in a timely manner. In this review article, we provide an overview of the clinical features, pathological findings and management principles of common immune-related toxicities, attempting to provide mechanistic insight into an increasingly common complication of cancer therapy.


Asunto(s)
Antineoplásicos Inmunológicos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedades del Sistema Endocrino/inducido químicamente , Enfermedades Gastrointestinales/inducido químicamente , Tolerancia Inmunológica/efectos de los fármacos , Inmunoterapia/efectos adversos , Enfermedades Pulmonares/inducido químicamente , Terapia Molecular Dirigida/efectos adversos , Neoplasias/tratamiento farmacológico , Animales , Enfermedad Hepática Inducida por Sustancias y Drogas/inmunología , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/terapia , Enfermedades del Sistema Endocrino/inmunología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/terapia , Enfermedades Gastrointestinales/inmunología , Enfermedades Gastrointestinales/metabolismo , Enfermedades Gastrointestinales/terapia , Humanos , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/metabolismo , Enfermedades Pulmonares/terapia , Neoplasias/inmunología , Neoplasias/metabolismo , Factores de Riesgo , Escape del Tumor/efectos de los fármacos
8.
Biochem Soc Trans ; 48(3): 915-931, 2020 06 30.
Artículo en Inglés | MEDLINE | ID: mdl-32412045

RESUMEN

Type 1 diabetes (T1D) and Hashimoto's thyroiditis (HT) are the two most common autoimmune endocrine diseases that have rising global incidence. These diseases are caused by the immune-mediated destruction of hormone-producing endocrine cells, pancreatic beta cells and thyroid follicular cells, respectively. Both genetic predisposition and environmental factors govern the onset of T1D and HT. Recent evidence strongly suggests that the intestinal microbiota plays a role in accelerating or preventing disease progression depending on the compositional and functional profile of the gut bacterial communities. Accumulating evidence points towards the interplay between the disruption of gut microbial homeostasis (dysbiosis) and the breakdown of host immune tolerance at the onset of both diseases. In this review, we will summarize the major recent findings about the microbiome alterations associated with T1D and HT, and the connection of these changes to disease states. Furthermore, we will discuss the potential mechanisms by which gut microbial dysbiosis modulates the course of the disease, including disruption of intestinal barrier integrity and microbial production of immunomodulatory metabolites. The aim of this review is to provide broad insight into the role of gut microbiome in the pathophysiology of these diseases.


Asunto(s)
Enfermedades del Sistema Endocrino/metabolismo , Microbioma Gastrointestinal , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/microbiología , Ácidos y Sales Biliares/metabolismo , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/microbiología , Progresión de la Enfermedad , Disbiosis/inmunología , Disbiosis/microbiología , Enfermedades del Sistema Endocrino/inmunología , Enfermedades del Sistema Endocrino/microbiología , Ácidos Grasos Volátiles/metabolismo , Predisposición Genética a la Enfermedad , Enfermedad de Hashimoto/inmunología , Enfermedad de Hashimoto/microbiología , Homeostasis , Humanos , Incidencia , Permeabilidad
9.
Hautarzt ; 71(10): 762-771, 2020 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-32886132

RESUMEN

Hidradenitis suppurativa (HS) is a chronic, recurrent cutaneous disease of the terminal hair follicle which manifests with deep-seated, painful nodules, abscesses, and sinus tract formation. The pathophysiology of the disease includes among various factors also dermatoendocrinologic variables: Correlations with metabolic syndrome, obesity, sex steroid hormones, and the improvement after antiandrogen therapy are some of the key points presented in this review. Hormonal treatment of HS can be an effective and inexpensive alternative or add-on therapy to classic HS treatments, especially in cases where antibiotics and/or biologics are ineffective or contraindicated.


Asunto(s)
Absceso/etiología , Enfermedades del Sistema Endocrino/metabolismo , Hormonas Esteroides Gonadales/metabolismo , Hidradenitis Supurativa/fisiopatología , Síndrome Metabólico/metabolismo , Antagonistas de Andrógenos/uso terapéutico , Diabetes Mellitus/metabolismo , Dislipidemias/metabolismo , Folículo Piloso , Hidradenitis Supurativa/tratamiento farmacológico , Hidradenitis Supurativa/metabolismo , Hormonas/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Obesidad/metabolismo
10.
J Pak Med Assoc ; 70(4): 757-761, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32296231

RESUMEN

Oncocrinology is the science which studies the complex bi-directional relationship between cancer and the endocrine system, including pathophysiological links, clinical presentation and the impact of cancer treatment and endocrine therapy. This review describes the vast spectrum of the complex, multifacted relationship between the endocrine system and malignancy. It also includes the endocrine aspects of anti-cancer treatment, and the need for oncovigilance with endocrine therapy.


Asunto(s)
Endocrinología , Oncología Médica , Antineoplásicos/efectos adversos , Antineoplásicos Hormonales/efectos adversos , Antineoplásicos Hormonales/uso terapéutico , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/etiología , Neoplasias de las Glándulas Endocrinas/complicaciones , Neoplasias de las Glándulas Endocrinas/etiología , Neoplasias de las Glándulas Endocrinas/metabolismo , Neoplasias de las Glándulas Endocrinas/terapia , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/terapia , Terapia de Reemplazo de Estrógeno/efectos adversos , Humanos , Hipoglucemiantes/efectos adversos , Neoplasias/complicaciones , Neoplasias/etiología , Neoplasias/metabolismo , Neoplasias/terapia , Obesidad/complicaciones , Obesidad/metabolismo , Síndromes Paraneoplásicos/etiología , Síndromes Paraneoplásicos/metabolismo , Pioglitazona/efectos adversos , Factores de Riesgo
11.
Am J Physiol Endocrinol Metab ; 317(5): E731-E741, 2019 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-31287713

RESUMEN

We previously demonstrated that androgen signaling expands pancreatic ß-cell mass in the sexual maturation period (Am J Physiol Endocrinol Metab 314: E274-E286, 2018). The aim of this study was to elucidate whether fetal androgen signaling plays important roles in ß-cell mass development and ß-cell function in adulthood, defects of which are associated with type 2 diabetes mellitus. In the pancreas of male fetuses, androgen receptor (AR) was strongly expressed in the cytoplasm and at the cell membrane of Nkx6.1-positive ß-cell precursor cells but was markedly reduced in insulin-positive ß-cells. Administration of the anti-androgen flutamide to pregnant dams during late gestation reduced ß-cell mass and Ki67-positive proliferating ß-cells at birth in a male-specific manner without affecting body weight. The decrease of ß-cell mass in flutamide-exposed male rats was not recovered when rats were fed a standard diet, whereas it was fully recovered when rats were fed a high-fat diet (HFD), at 6 and 12 wk of age. Flutamide exposure in utero led to the development of glucose intolerance in male rats due to a decrease in insulin secretion when fed HFD but not standard diet. Insulin sensitivity did not differ between the two groups irrespective of diet. These results indicated that the action of fetal androgen contributed to ß-cell mass expansion in a sex-specific manner at birth and to the development of glucose intolerance by decreasing the secretion of insulin in HFD-fed male rats. Our data demonstrated the involvement of fetal androgen signaling in hypothesized sex differences in the developmental origins of health and disease by affecting pancreatic ß-cell function.


Asunto(s)
Andrógenos/metabolismo , Dieta Alta en Grasa , Enfermedades del Sistema Endocrino/patología , Feto/fisiopatología , Intolerancia a la Glucosa/metabolismo , Células Secretoras de Insulina/patología , Antagonistas de Andrógenos/farmacología , Animales , Composición Corporal , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/fisiopatología , Femenino , Flutamida/farmacología , Intolerancia a la Glucosa/etiología , Secreción de Insulina/efectos de los fármacos , Metabolismo de los Lípidos , Masculino , Embarazo , Ratas , Ratas Wistar , Receptores Androgénicos/biosíntesis , Receptores Androgénicos/genética , Caracteres Sexuales , Transducción de Señal
12.
Endocr Res ; 44(1-2): 27-45, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30198791

RESUMEN

PURPOSE: The purpose of this article is to review recent literature regarding endocrine disorders related to celiac disease (CD). METHODS: We describe a case report and review existing literature on the endocrine manifestations of CD. RESULTS: CD is an autoimmune disorder characterized by intestinal inflammation in response to gluten. CD can cause a wide range of extra-intestinal complications, including endocrine manifestations. Metabolic bone disease including osteoporosis and osteopenia, vitamin D deficiency, secondary hyperparathyroidism and less frequently osteomalacia can be seen. In CD, fracture risk is increased by 30-40%, while risk for hip fracture is approximately doubled. The risk for other endocrine disorders, particularly autoimmune endocrinopathies, is also increased in those with CD compared to the general population. Epidemiologic data indicate the risk for hypothyroidism is 3-4 times higher among those with CD, while risk of type 1 diabetes is greater than double. Risk for primary adrenal insufficiency is a striking 11-fold higher in those with versus without CD, though the absolute risk is low. Fertility is reduced in women with CD before diagnosis by 37% while male fertility in the absence of hypogonadism does not appear to be affected. Other endocrine conditions including hyperthyroidism, ovarian failure, androgen insensitivity, impaired growth and growth hormone deficiency and autoimmune polyendocrine syndromes have also been associated with CD. CONCLUSIONS: CD is associated with a wide range of endocrine manifestations.


Asunto(s)
Enfermedad Celíaca/complicaciones , Enfermedades del Sistema Endocrino/etiología , Enfermedad Celíaca/metabolismo , Enfermedades del Sistema Endocrino/metabolismo , Humanos , Hipotiroidismo/etiología , Hipotiroidismo/metabolismo , Masculino , Persona de Mediana Edad , Osteoporosis/etiología , Osteoporosis/metabolismo
13.
Int J Mol Sci ; 20(11)2019 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-31212642

RESUMEN

Secondary nonalcoholic fatty liver disease (NAFLD) defines those complex pathophysiological and clinical consequences that ensue when the liver becomes an ectopic site of lipid storage owing to reasons other than its mutual association with the metabolic syndrome. Disorders affecting gonadal hormones, thyroid hormones, or growth hormones (GH) may cause secondary forms of NAFLD, which exhibit specific pathophysiologic features and, in theory, the possibility to receive an effective treatment. Here, we critically discuss epidemiological and pathophysiological features, as well as principles of diagnosis and management of some common endocrine diseases, such as polycystic ovary syndrome (PCOS), hypothyroidism, hypogonadism, and GH deficiency. Collectively, these forms of NAFLD secondary to specific endocrine derangements may be envisaged as a naturally occurring disease model of NAFLD in humans. Improved understanding of such endocrine secondary forms of NAFLD promises to disclose novel clinical associations and innovative therapeutic approaches, which may potentially be applied also to selected cases of primary NAFLD.


Asunto(s)
Enfermedades del Sistema Endocrino/epidemiología , Enfermedades del Sistema Endocrino/patología , Enfermedad del Hígado Graso no Alcohólico/epidemiología , Animales , Enfermedades del Sistema Endocrino/metabolismo , Femenino , Humanos , Hipogonadismo/epidemiología , Hipogonadismo/metabolismo , Hipogonadismo/patología , Hipotiroidismo/epidemiología , Hipotiroidismo/metabolismo , Hipotiroidismo/patología , Masculino , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/patología , Síndrome del Ovario Poliquístico/epidemiología , Síndrome del Ovario Poliquístico/metabolismo , Síndrome del Ovario Poliquístico/patología
14.
Vet Clin North Am Equine Pract ; 35(3): 399-417, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31587976

RESUMEN

The donkey evolved under harsh and arid environmental conditions, developing unique energy-efficiency traits, with an efficiency to rapidly mobilize fat in situations of increased energy demands or when food is scarce. This evolution has led to an inherent predisposition of donkeys to obesity, dyslipidemias, insulin dysregulation/metabolic syndrome, pituitary pars intermedia dysfunction, and endocrinopathic laminitis. Marked differences have been described in hormone dynamics and testing protocols for the diagnosis of these endocrine and metabolic diseases in donkeys compared with horses, underlining the necessity of a species-specific approach in order to avoid misdiagnosis, unnecessary or inadequate treatments, and additional costs.


Asunto(s)
Enfermedades del Sistema Endocrino/veterinaria , Equidae , Enfermedades de los Caballos/diagnóstico , Enfermedades Metabólicas/veterinaria , Animales , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/terapia , Enfermedades de los Caballos/metabolismo , Enfermedades de los Caballos/terapia , Caballos , Enfermedades Metabólicas/diagnóstico , Enfermedades Metabólicas/metabolismo , Enfermedades Metabólicas/terapia
15.
Pak J Pharm Sci ; 32(1): 231-239, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30772815

RESUMEN

Zinc is essential in the regulation of a variety of physiological and biochemical events in the organism. It plays a critical role in maintaining the cell membrane integrity, protein-carbohydrate-lipid metabolism, immune system, wound injury and in the regulation of a number of other biological processes associated with normal growth and development. Physiological and biochemical levels of many hormones are affected by zinc metabolism. Therefore, growth impairment, hypogonadism, and some endocrine diseases are associated with the deficiency of zinc. These effects of zinc are considered versatile. Zinc increases the synthesis of the growth hormone and its number of receptors; thus, it is an important mediator in the binding of this hormone to its receptor. Found in a large quantity in the pancreas tissue, zinc has a part in the regulation of the effect of insulin. Zinc is involved to much more thyroid hormone metabolism such as hormone synthesis, receptor activity, conversion of T4 to T3, and production of carrier proteins. The low levels of zinc and high levels of leptin in obese individuals point to a critical relationship between zinc and leptin. Zinc is related to enzyme activity to melatonin synthesis. Melatonin has regulatory activity for zinc absorption from gastrointestinal system. Zinc particularly affects the conversion of testosterone to dihydrotestosterone, as 5α-reductase that is involved in this conversion is a zinc-dependent enzyme. In consideration of these relations, zinc is accepted to play critical roles in the endocrine system. The aim of the current review is to draw attention to the effects of zinc on the endocrine system.


Asunto(s)
Enfermedades del Sistema Endocrino/metabolismo , Sistema Endocrino/metabolismo , Hormonas/metabolismo , Zinc/metabolismo , Animales , Sistema Endocrino/fisiopatología , Enfermedades del Sistema Endocrino/fisiopatología , Humanos , Vías Secretoras
16.
Biochim Biophys Acta Biomembr ; 1860(1): 124-140, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28284720

RESUMEN

It has long been known that the main secretory cells of exocrine and endocrine glands are connected by gap junctions, made by a variety of connexin species that ensure their electrical and metabolic coupling. Experiments in culture systems and animal models have since provided increasing evidence that connexin signaling contributes to control the biosynthesis and release of secretory products, as well as to the life and death of secretory cells. More recently, genetic studies have further provided the first lines of evidence that connexins also control the function of human glands, which are central to the pathogenesis of major endocrine diseases. Here, we summarize the recent information gathered on connexin signaling in these systems, since the last reviews on the topic, with particular regard to the pancreatic beta cells which produce insulin, and the renal cells which produce renin. These cells are keys to the development of various forms of diabetes and hypertension, respectively, and combine to account for the exploding, worldwide prevalence of the metabolic syndrome. This article is part of a Special Issue entitled: Gap Junction Proteins edited by Jean Claude Herve.


Asunto(s)
Conexinas/metabolismo , Glándulas Endocrinas/metabolismo , Enfermedades del Sistema Endocrino/metabolismo , Uniones Comunicantes/metabolismo , Transducción de Señal , Animales , Glándulas Endocrinas/patología , Enfermedades del Sistema Endocrino/patología , Uniones Comunicantes/patología , Humanos
17.
Calcif Tissue Int ; 102(3): 348-357, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29098359

RESUMEN

An autosomal-recessive inactivating mutation R272Q in the human intestinal cell kinase (ICK) gene caused profound multiplex developmental defects in human endocrine-cerebro-osteodysplasia (ECO) syndrome. ECO patients exhibited a wide variety of skeletal abnormalities, yet the underlying mechanisms by which ICK regulates skeletal development remained largely unknown. The goal of this study was to understand the structural and mechanistic basis underlying skeletal anomalies caused by ICK dysfunction. Ick R272Q knock-in transgenic mouse model not only recapitulated major ECO skeletal defects such as short limbs and polydactyly but also revealed a deformed spine with defective intervertebral disk. Loss of ICK function markedly reduced mineralization in the spinal column, ribs, and long bones. Ick mutants showed a significant decrease in the proliferation zone of long bones and the number of type X collagen-expressing hypertrophic chondrocytes in the spinal column and the growth plate of long bones. These results implicate that ICK plays an important role in bone and cartilage development by promoting chondrocyte proliferation and maturation. Our findings provided new mechanistic insights into the skeletal phenotype of human ECO and ECO-like syndromes.


Asunto(s)
Huesos/metabolismo , Enfermedades del Sistema Nervioso Central/metabolismo , Condrocitos/metabolismo , Enfermedades del Sistema Endocrino/metabolismo , Músculo Esquelético/fisiopatología , Proteínas Serina-Treonina Quinasas/metabolismo , Animales , Densidad Ósea , Diferenciación Celular/fisiología , Proliferación Celular/fisiología , Modelos Animales de Enfermedad , Humanos , Ratones Transgénicos , Transducción de Señal/fisiología
18.
Gan To Kagaku Ryoho ; 45(7): 1031-1035, 2018 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-30042266

RESUMEN

Cytotoxic T-lymphocyte associated antigen 4(CTLA-4), programmed death 1(PD-1), and programmed death-ligand 1 (PD-L1)are referred to as immune-checkpoints. CTLA-4 is located on the surface of activated T-cells, therefore inhibiting binding of CD28 to B7 molecule on antigen presenting cells. The CTLA-4 pathway predominantly acts in lymph nodes. PD-1 is majorly expressed on T-cells. The PD-1 pathway is involved with tumor microenvironment. Immune-checkpoint inhibitors (ICIs)are monoclonal antibodies to these molecules and are promising novel agents for malignant tumor treatment. ICIs promote T-cell-mediated cytotoxicity directed at cancer cell antigens. Approximately 20-30% of patients with advanced cancer were found to be responders of ICIs. However, various adverse events have been reported as immune-related adverse events(irAEs). IrAEs include dermatological, gastrointestinal, hepatic, neurological, and endocrine disorders. In the endocrine system, irAEs in the pituitary glands, thyroid glands, pancreas, and adrenal glands have been reported. Since rapidly progressive fatal endocrine systems failure may provoke during ICI therapy, precise diagnosis and prompt treatment as well as close follow-up is critical. We propose routine monitoring of endocrine functions and related symptoms(ie. worsened fatigue, hyperglycemia, hypoglycemia, hypotension, and hyponatremia), as well as other laboratory tests during ICI therapy. We herein discuss possible mechanisms of endocrine irAEs with ICIs, and highlight diagnostic approaches, treatments, and future prospects of endocrine irAEs during ICI therapy.


Asunto(s)
Antineoplásicos/efectos adversos , Enfermedades del Sistema Endocrino/inducido químicamente , Terapia Molecular Dirigida/efectos adversos , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Antineoplásicos/uso terapéutico , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/fisiopatología , Humanos
19.
Ann Hematol ; 96(6): 995-1003, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28321531

RESUMEN

We report the first evaluation of bone quality in 70 thalassemia intermedia (TI) patients (37 males, 33 females, age 41 ± 12 years). Thirty-three patients (47%) had been transfused, 34 (49%) had been splenectomized, 39 (56%) were on iron chelation therapy, and 11 (16%) were on hydroxyurea. Mean hemoglobin was 9.2 ± 1.5 g/dl, median ferritin 537 ng/dl (range 14-4893), and mean liver iron concentration 7.6 ± 6.4 mg Fe/g dw. Fifteen patients (21%) had endocrinopathies, and 29 (41%) had vitamin D deficiency. Bone quantity (bone mineral density, BMD) and bone quality (trabecular bone score, TBS) were evaluated by densitometry. In 53/70 patients (76%), osteopathy was found (osteoporosis in 26/53, osteopenia in 27/53). BMD values were higher in the never-transfused patients and in the not-chelated group. A highly significant correlation was found between splenectomy and BMD at all the sites, with lower values in the splenectomized patients. TBS values were significantly lower in TI patients than in 65 non-thalassemic controls (1.22 vs 1.36, p < 0.01), mainly in those splenectomized and in the transfused and chelated groups (p < 0.01). TBS did not correlate with liver iron concentration values. Our data disclose the major role of non-invasive bone quality evaluation in TI patients, especially those with the worst health state, to obtain a comprehensive assessment of fracture risk. Splenectomy seems to play a major part in bone complications.


Asunto(s)
Densidad Ósea , Huesos/metabolismo , Talasemia beta/metabolismo , Absorciometría de Fotón , Adulto , Enfermedades Óseas Metabólicas/complicaciones , Enfermedades Óseas Metabólicas/metabolismo , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/metabolismo , Femenino , Humanos , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/metabolismo , Masculino , Persona de Mediana Edad , Osteoporosis/complicaciones , Osteoporosis/metabolismo , Talasemia beta/complicaciones
20.
Int J Mol Sci ; 18(2)2017 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-28208663

RESUMEN

The endoplasmic reticulum (ER) is the organelle where secretory and membrane proteins are synthesized and folded. Unfolded proteins that are retained within the ER can cause ER stress. Eukaryotic cells have a defense system called the "unfolded protein response" (UPR), which protects cells from ER stress. Cells undergo apoptosis when ER stress exceeds the capacity of the UPR, which has been revealed to cause human diseases. Although neurodegenerative diseases are well-known ER stress-related diseases, it has been discovered that endocrine diseases are also related to ER stress. In this review, we focus on ER stress-related human endocrine disorders. In addition to diabetes mellitus, which is well characterized, several relatively rare genetic disorders such as familial neurohypophyseal diabetes insipidus (FNDI), Wolfram syndrome, and isolated growth hormone deficiency type II (IGHD2) are discussed in this article.


Asunto(s)
Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/metabolismo , Estrés del Retículo Endoplásmico , Animales , Modelos Animales de Enfermedad , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/terapia , Humanos , Mamíferos , Transducción de Señal , Respuesta de Proteína Desplegada
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA